ZymoGenetics at buy by Merrill

Merrill Lynch analyst Hari Sambasivam rated ZymoGenetics, Inc. at a buy following the company's release of preliminary results from two phase 1b studies showed TACI-Ig for systemic lupus erythematosus (SLE) was safe and well-tolerated (primary endpoint) with both subcutaneous and intravenous administration. Shares of the Seattle-based pharmaceutical company were up 81 cents, or 4.83%, at $17.57 on volume of 198,585 shares versus the three-month running average of 307,347 shares. (Nasdaq: ZGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.